Gilead Sciences : FDA Expands Biktarvy Indication For HIV Treatment
(RTTNews) - The U.S. Food and Drug Administration approved a new, expanded indication for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat people with HIV or PWH who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance, Gilead Sciences Inc. (GILD) said in a statement.
HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for people with HIV.
The M184V/I resistance mutation has been found to be present in a range (22-63%) of PWH with pre-existing resistance to nucleoside reverse transcriptase inhibitors (NRTIs) across various HIV subtypes. This label update is supported by Study 4030, which evaluated the efficacy, safety, and tolerability profile of Biktarvy in a broad range of people with HIV-1 with or without pre-existing NRTI resistance, including those with the M184V/I resistance.
The company noted that Biktarvy is now the first and only integrase strand transfer inhibitor (INSTI)-based single-tablet regimen that is FDA approved and U.S. Department of Health and Human Services (DHHS) guideline recommended for PWH who are virally suppressed with M184V/I resistance.
For More Such Health News, visit rttnews.com
